Annals of the Rheumatic Diseases | ARD is an international peer-reviewed journal covering all aspects of rheumatology, including musculoskeletal conditions, arthritic disease and connective tissue disorders.

Intro Widget

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.

ARD is an official journal of EULAR.

Free lay summaries are provided for selected research articles. You can keep up with the latest news via Twitter and Facebook.

Editor-in-Chief: Professor Josef Smolen, University of Vienna, Austria
Editorial team

Impact Factor: 12.350

Authors

Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.

The Author Information section provides general guidelines and requirements for specific article types.

Information is also provided on editorial policies and open access.

Impact Factor: 12.350

Author information

Submit a paper

Intro Widget

Latest Articles

Clinical and epidemiological research:

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?

Letter:

Two distinct clinical phenotypes of pulmonary arterial hypertension secondary to systemic lupus erythematosus

Letter:

Significant joint-destructive association of HLA-DRB1*04:05 independent of DAS28 in rheumatoid arthritis

Review:

Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities

Basic and translational research:

Increased autophagy is cytoprotective against podocyte injury induced by antibody and interferon-α in lupus nephritis

Altmetrics

Related Journals

Most Read Articles

Recommendation:

2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis

Recommendation:

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR)

Recommendation:

2018 update of the EULAR recommendations for the management of Behçet’s syndrome

Clinical and epidemiological research:

Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and meta-analysis

Clinical and epidemiological research:

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Authors